Sean Reilly, DAIC Publisher

Sean Reilly is healthcare brands group publisher (Imaging Technology News and Diagnostic and Interventional Cardiology) at Scranton Gillette Communications.

Blog | Sean Reilly, DAIC Publisher | January 09, 2013

Innovation Exasperation

In a recent LinkedIn Medical Device Group posting, it was noted that DuVal & Associates, P.A. filed a Citizen Petition and Petition for Stay of Action with the FDA, on behalf of the Minnesota Medical Device Alliance (MMDA). See:

The petition challenges the FDA's practices and interpretations for reviewing 510(k)s and asks the Commissioner to stay the implementation of “Draft Guidance: Evaluating Substantial Equivalence in Premarket Notifications [510(k)],” dated December 27, 2011. It seeks reversion to older guidance until FDA addresses:

Its practice of “stage-gating” reviews (because it leads to an inevitable FDA request to pursue the de novo path); Its interpretation of “general versus specific intended use,” now applied so narrowly that FDA considers almost every new indication for a 510(k) device to be a new intended use; Its interpretation of clinical utility/benefit as part of the substantial equivalence (SE) criteria (because it essentially allows FDA to determine which devices practitioners should use); Its inappropriate use of statutes and regulatory matters extraneous to the SE decision (e.g., cGMP/Quality Systems, MDR, FD&C Act advertising and promotion, and OSHA regulations or CDC guidance); Its application of risk mitigation and “assurance case” principles to 510(k) clearance criteria; Its interpretation when a device has a new technological characteristic which raises new questions of safety and effectiveness; Its failure in stage-gated reviews to review performance data to determine same intended use / technological characteristics and if new safety and effectiveness questions need to be asked; Its practice of dictating the non-clinical and clinical performance data an applicant must generate (instead of reviewing submitted data at face value for an SE decision); and, Its approach to “whistleblowing,” which can lead to risk-averseness for political, not safety, reasons.


The petition seems on the mark. Medical device companies are under enormous financial pressures with difficult economies both domestically and abroad. Add to this the 2.3% medical device tax on gross revenues and a highly bureaucratic, overbearing (if you agree with this petition) FDA and you can’t help but envision difficult times ahead for our industry. Innovative small and midsize companies are struggling, and the government and the FDA aren’t helping matters by treating innovation as the problem. Many on the device side seem unable or unwilling to challenge the FDA bureaucracy.  Win the battle but lose the war, perhaps? As one CEO recently shared, "Challenging [the FDA] might make me feel better but it won't resolve the problem." A real shame as, according to this petition, the FDA and some of its policies need to be challenged.

I agree with this petition that the United States may fall behind other countries in having access to state-of-the-art medical devices while they still are state-of-the-art. That ship may have already sailed, in fact. I also agree that innovation – something we have always embraced and encouraged as a great nation – is being thwarted rather than supported. Healthcare consumers and innovative device companies are suffering and will continue to do so if changes aren’t made. 

Despite said doom and gloom, some innovative, well-managed companies will blast through the aforementioned roadblocks and become stronger, particularly as competition drops off. But I’m concerned that it's going to be mostly the largest companies that survive, and innovation might not always be their strongest suit. I’m also concerned that, as competition disappears, medical device prices will increase – not good for consumers or our Healthcare System.

There is a symbiotic relationship between healthcare providers, healthcare consumers, device manufacturers, our government and the FDA. Sadly, the later have too much power and our system, as this petition suggests, is out of balance and in need of correction. If you agree, beat the drums!

Related Content

PICOM, Scimage, Cardiac PACS, CVIS

ScImage's PICOM system is an example of a CVIS that unifies the IT needs of several cardiovascular service lines into a single cardiology department reporting and image management system. This includes cardiac imaging, echo, ECG management and cath lab reporting. 

Feature | Cardiac PACS| October 08, 2015 | Dave Fornell
Cardiovascular information systems (CVIS or cardiac PACS) have undergone a transformation over the past few years to
CMS, Stage 3 Meaningful Use final rule, ONC, healthcare IT, electronic health records, EHR
Feature | Information Technology| October 07, 2015
The Centers for Medicare and Medicaid Services (CMS) released the final version of Stage 3 Meaningful Use (MU)...
ONC, Federal Health IT Strategic Plan 2015-2020, information technology, healthcare
Feature | Information Technology| September 22, 2015
The U.S. Department of Health and Human Services’ Office of the National Coordinator for Health Information Technology...
Frost & Sullivan, top medical technologies, growth, healthcare

Corindus CorPath Vascular Robotic System image courtesy of Corindus Vascular Robotics.

Feature | Information Technology| September 22, 2015
Frost & Sullivan released its list of top medical technologies for 2015, featuring an array of sophisticated...

Big data from regional health exchanges can help identify patients who are at high risk for developing cardiovascular disease and stroke based on blood pressure readings and trends from their office visits over time that arestored in the electronic health records. This information can be used to target these patients with more followups, education and more intensive prevention programs. 

Feature | Information Technology| September 22, 2015 | Jeff Zagoudis and Dave Fornell
As healthcare converts to an entirely electronic health record (EHR)-based system, it opens up new opportunities to m
McKesson Cardiology, CVIS, cardiovascular information system, cardiac PACS
Feature | Cardiac PACS| September 11, 2015 | Shawn McKenzie, MPA, president, CEO, and Val Kapitula, Ascendian Healthcare Consulting
The cardiovascular service line, whether existing within the confines of an acute-care environment or outpatient sett
McKesson Cardiology, CVIS, cardiovascular information system, cardiac PACS
Feature | Cardiac PACS| September 11, 2015 | Dave Fornell
For any cardiology department looking to upgrade or replace its...
McKesson Cardiology, CVIS
Feature | Cardiac PACS| September 11, 2015 | Dave Fornell
Two key requirements for today’s cardiovas...
uberization of healthcare

Physicians are starting to "prescribe" smartphone apps to patients for education, tracking their health or to interface with wearable monitor devices. This physician is using an app created by the American College of Cardiology (ACC) to educate a patient about cardiac function.


Feature | Business| September 04, 2015 | Dave Fornell
Today, in a world of immediate access to information anywhere on the planet using a smartphone, consumers expect more
ICD-10, transition, practices, Richard Milam, EnableSoft, robotic process automation, software testing, education, communication
News | Business| August 13, 2015
Many organizations may be rallying employees and resources in order to make the switch from the ICD-9 to the ICD-10...
Overlay Init